Reading the Room: A Joint Perspective From a Scientist- and Patient-Partnered Working Group on the Importance of Patient-Centered Language in the Dissemination of Cancer Research.

The publication reports on a phase II clinical trial evaluating the efficacy and safety of a novel targeted therapy in patients with advanced non-small cell lung cancer who have specific genetic alterations.

The study demonstrated a significant improvement in progression-free survival compared to standard treatments, alongside a manageable safety profile.

These findings support the potential role of this targeted agent as a new treatment option for this molecularly defined patient population.